Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).
Launched by UCB PHARMA · Feb 10, 2006
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male/female adult subjects (≥ 16 or 18 years)
- • Diagnosis of epilepsy (all types of seizures may be included)
- • Subjects who completed N01175 (NCT00175903) trial and benefited from levetiracetam monotherapy
- • Other inclusion criteria may apply
- Exclusion Criteria:
- • Subjects withdrawn from N01175 (NCT00175903) trial for any reason
- • Subjects who received treatment other than levetiracetam in N01175 (NCT00175903) trial
- • Subject requiring add-on antiepileptic treatment
- • Subjects from countries where levetiracetam is authorized for use as monotherapy in epilepsy treatment
- • Sexually active woman with childbearing potential who is not using a medically accepted birth control method
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warszawa, , Poland
Kortrijk, , Belgium
Lille, , France
Krakow, , Poland
Edegem, , Belgium
Oostende, , Belgium
Brest, , France
Warszawa, , Poland
Zurich, , Switzerland
Gent, , Belgium
Poznan, , Poland
Leuven, , Belgium
Brugge, , Belgium
Sofia, , Bulgaria
Czestochowa, , Poland
Rennes, , France
Tampere, , Finland
Bordeaux, , France
Varna, , Bulgaria
Bordeaux, , France
Nancy, , France
Lausanne, , Switzerland
Kuopio, , Finland
Tampere, , Finland
Haine St Paul, , Belgium
Jette, , Belgium
Hus (Helsinki), , Finland
Blaye, , France
Carcassonne, , France
Cherbourg, , France
Saint Brieuc, , France
Saint Quentin, , France
Toulouse Cedex 04, , France
Valenciennes, , France
Olstyn, , Poland
Biel, , Switzerland
St Gallen, , Switzerland
Sofia, , Bulgaria
Varna, , Bulgaria
Lyon Cedex, , France
Patients applied
Trial Officials
UCB Clinical Trial Call Center
Study Director
+1 877 822 9493 (UCB)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials